Skip to content

Search

T regulatory cells in childhood asthma

Asthma is a chronic disease of the airways, most commonly driven by immuno-inflammatory responses to ubiquitous airborne antigens.

Pregnancy and Early Life Immunology

The Pregnancy and Early Life Immunology team's overall research vision is targeted towards understanding immunological development during early life.

Epigenetic changes underpinning allergen sensitization: a twin-based study

We are studying immune cells from identical twins of which one suffers and one does not suffer from allergic disease to identify specific mechanisms that may play important roles in disease development.

Finding the cellular explanation for recurrent asthma exacerbations

This study is designed to identify the specific unique immune cell response that occurs in these children with recurrent disease.

The cellular effects of estrogen on allergic asthma

The study aims to identify the mechanism for this so that this knowledge can be used to better treat asthma and allergies in both males and females.

Mechanisms of IgE sensitization

This project investigates how cells of the immune system respond to substances to cause allergies to help develop new treatments.

Treatment with inhaled aerosolised ethanol reduces viral load and potentiates macrophage responses in an established influenza mouse model

Treatment options for viral lung infections are currently limited. We aimed to explore the safety and efficacy of inhaled ethanol in an influenza-infection mouse model.

LPS binding protein and activation signatures are upregulated during asthma exacerbations in children

Asthma exacerbations in children are associated with respiratory viral infection and atopy, resulting in systemic immune activation and infiltration of immune cells into the airways. The gene networks driving the immune activation and subsequent migration of immune cells into the airways remains incompletely understood. Cellular and molecular profiling of PBMC was employed on paired samples obtained from atopic asthmatic children during acute virus-associated exacerbations and later during convalescence.

Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy

No approved treatment for peanut allergy exists for children younger than 4 years of age, and the efficacy and safety of epicutaneous immunotherapy with a peanut patch in toddlers with peanut allergy are unknown.